2018 Clinic PET Scan 
AuntMinnie
DECEMBER 19, 2023
Clinical brain imaging with a newly developed portable PET scanner appears feasible, with a comparison to conventional PET imaging for the first time revealing similar results in human subjects, according to a group in New York City. In 2018, the group received a grant from the U.S.
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
MAY 31, 2023
CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Measurement follows NEMA NU 2-2018. [v] iv] Omni Legend 32 cm has up to 2.2 ix Mehranian, A.,
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.
Imaging Technology
MAY 2, 2023
The ability to determine the extent and location of recurrent prostate cancer to inform appropriate clinical management for these men is key for physicians and their patients, because up to 50% of patients who undergo radiation therapy will develop local or distant recurrences within 10 years,” said Brian T. across all regions.
Imaging Technology
MAY 30, 2023
All of us at Blue Earth Diagnostics want to express our sincere gratitude to the many patients, physicians, clinical trial sites and collaborators who have worked closely with us to progress POSLUMA.” Results demonstrated high detection rates (% positive PET scans) even at low PSA levels.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S.
Expert insights. Personalized for you.
122 
Let's personalize your content